BioMarin Pharma (BMRN) Tops Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. ORCL

Go back to BioMarin Pharma (BMRN) Tops Q3 EPS by 11c

BioMarin Reports Third Quarter 2026 Financial and Operating Results

November 2, 2026 4:03 PM EST

Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y

Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges

Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio

PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH)

Conference Call and Webcast Scheduled... More